

- from the human large intestine. *J Appl Bacteriol* 1988; 65: 241-7.
- 8 Gibson GR, Cummings JH, Macfarlane GT. Use of a three-stage continuous culture system to study the effect of mucin on dissimilatory sulfate reduction and methanogenesis by mixed populations of human gut bacteria. *Appl Environ Microbiol* 1988; 54: 2750-5.
 - 9 Christl SU, Gibson GR, Cummings JH. Role of dietary sulphate in the regulation of methanogenesis in the human large intestine. *Gut* 1992; 33: 1234-8.
 - 10 Oremland RS, Taylor BF. Sulfate reduction and methanogenesis in marine sediments. *Geochimica et Cosmochimica Acta* 1978; 42: 209-14.
 - 11 Kristjansson JK, Schönheit P, Thauer RK. Different K_s values for hydrogen of methanogenic bacteria and sulfate reducing bacteria: an explanation for the apparent inhibition of methanogenesis by sulfate. *Arch Microbiol* 1982; 131: 278-82.
 - 12 Thauer RK, Jungermann K, Decker K. Energy conservation in chemotrophic anaerobic bacteria. *Bacteriol Rev* 1977; 41: 100-80.
 - 13 Florin T, Neale G, Gibson GR, Christl SU, Cummings JH. Metabolism of dietary sulphate: absorption and excretion in humans. *Gut* 1991; 32: 766-73.
 - 14 Strocchi A, Furne JK, Ellis CJ, Levitt MD. Competition for hydrogen by human faecal bacteria: evidence for the predominance of methane producing bacteria. *Gut* 1991; 32: 1498-501.
 - 15 Postgate JR. *The sulphate-reducing bacteria*. 2nd edition. Cambridge: Cambridge University Press. 1984.
 - 16 Florin THJ. Hydrogen sulphide and total acid-volatile sulphide in faeces, determined with a direct spectrophotometric method. *Clin Chim Acta* 1991; 196: 127-34.
 - 17 Strocchi A, Levitt MD. Factors affecting hydrogen production and consumption by human fecal flora. *J Clin Invest* 1992; 89: 1304-11.
 - 18 Florin THJ, Jabbar JA. Factors controlling human bowel metabolism. The effect of bile on methanogenesis. *J Gastroenterol Hepatol* 1992; 7: A21.
 - 19 Miller TL, Wolin MJ. Enumeration of *Methanobrevibacter smithii* in human feces. *Arch Microbiol* 1982; 131: 14-8.
 - 20 Miller TL, Wolin MJ. *Methanosphaera stadtmaniae* gen. nov., sp. nov. a species that forms methane by reducing methanol with hydrogen. *Arch Microbiol* 1985; 141: 116-22.
 - 21 McLeod GM, Wiggins HS. Bile-salts in small intestinal contents after ileal resection and in other malabsorption syndromes. *Lancet* 1968; i: 873-6.
 - 22 Percy Robb IW, Jalan KN, McManus JPA, Sircus W. Effect of ileal resection on bile salt metabolism in patients with ileostomy following proctocolectomy. *Clin Sci* 1971; 41: 371-82.
 - 23 Mekhjian HS, Phillips SF, Hofmann AF. Colonic absorption of unconjugated bile acids. Perfusion studies in man. *Dig Dis Sci* 1979; 7: 545-50.
 - 24 Stadler J, Stern HS, Sing Yeung KA, McGuire V, Furrer R, Marcon N, et al. Effect of high fat consumption on cell proliferation activity of colorectal mucosa and on soluble faecal bile acids. *Gut* 1988; 29: 1326-31.

Thyroid function and interferon treatment in chronic hepatitis C

EDITOR.—We read with much interest the article by Marcellin *et al* (*Gut* 1992; 33: 855-6) about two cases of sustained hypothyroidism induced by recombinant α interferon in patients with chronic hepatitis C. The presence of antithyroid antibodies in both patients suggested an autoimmune cause of the hypothyroidism.^{1,2}

We have recently seen a 51 year old woman with chronic active hepatitis C proved on biopsy examination randomised to receive 3 MU of recombinant interferon alfa 2-b (INTRON-A, Schering-Plough Corporation) subcutaneously three times a week for six months. The patient had no history of thyroid disease and had not received any drug known to be toxic to the thyroid. Serum triiodothyronine, thyroxine, free thyroxine, and thyroxine binding globulin were determined by RIA kits (Farnos Diagnostica Ltd, Turku, Finland); serum thyroid stimulating hormone,

thyroid microsomal antigen autoantibodies, and thyroglobulin autoantibodies were measured by IRMA kits (Biocode, Switzerland). Serum samples were collected before treatment and every month for 12 months thereafter.

A transient reduction in triiodothyronine, thyroxine free thyroxine values started at month 4 and an increase in thyroid stimulating hormone values was recorded (Figure). The patient had no clinical signs of hypothyroidism; thyroid autoantibodies remained negative. On this basis, we suggest a multifactorial cause of thyroid function change induced by recombinant α interferon. In our case, a direct inhibition of thyroid hormone synthesis and secretion, or both by recombinant α interferon could have played a determinant role. This mechanism has been shown by *in vitro* experiments with γ interferon.^{3,4}

A PICCIOTTO
G VARAGONA
P CIANCIOSI
R FRANCESCHINI
A GARIBALDI
G CELLE

Department of Internal Medicine,
University of Genoa,
Genoa, Italy

- 1 Fentiman IS, Balkwill FR, Thomas BS, Russel MJ, Todd I, Bottazzo GF. An autoimmune aetiology for hypothyroidism following interferon therapy for breast cancer. *Eur J Cancer Clin Oncol* 1988; 24: 1299-1303.
- 2 Fentiman IS, Thomas BS, Balkwill FR, Rubens RD, Hayward JL. Primary hypothyroidism associated with interferon therapy of breast cancer. (Letter). *Lancet* 1985; i: 1166.
- 3 Nagayama Y, Izumi M, Ashizawa K, Kiriyaama T, Yokoyama N, Morita S, et al. Inhibitory effect of interferon-gamma on the response of human thyrocytes to Thyrotropin (TSH) stimulation: relationship between the response to TSH and the expression of DR antigen. *J Clin Endocrinol Metab* 1987; 64: 949-53.
- 4 Ashizawa K, Yamashita S, Nagayama Y, Kimura H, Hirayu H, Izumi M, et al. Interferon-gamma inhibits thyrotropin-induced thyroid peroxidase gene expression in cultured human thyrocytes. *J Clin Endocrinol Metab* 1989; 69: 475-7.

Reply

EDITOR.—We read with interest the comment by Picciotto *et al* on our paper reporting another case of hypothyroidism, probably induced by recombinant interferon alfa 2-b in a patient treated for chronic hepatitis C. No antithyroid antibodies were found and the authors suggest a multifactorial mechanism by which thyroid abnormalities are induced.

We agree that, in the absence of antithyroid antibodies, the role of a direct inhibition of thyroid hormone synthesis and secretion by α interferon, or both, might be considered. Indeed, among 22 patients developing thyroid abnormalities while receiving interferon, we found antithyroid antibodies (anti-thyroglobulin and anti-peroxydase) in only half of them (unpublished data). *Ex vivo* studies of patients' thyroid cells, if considered ethical, might provide pertinent information about the mechanisms of the cell damage induced by interferon in these patients.

P MARCELLIN
M POUTEAU
N COLAS LINHART
B BOK
J-P BENHAMOU

Services d'Hépatologie, de
Médecine Nucléaire et de Biophysique
et Consultation de Médecine,
Hôpital Beaujon,
Clichy, France

Biliary endoprosthesis and common bile duct stones

EDITOR.—The report from Peters *et al* (*Gut* 1992; 33: 1412-5) of a group of patients with bile duct stones treated with a biliary endoprosthesis is of considerable interest. This technique has been used by many centres, provides excellent immediate drainage, and reasonable medium term results – but I wish to sound a note of caution. The justification for using stents as permanent treatment must depend on the results in the long term, indeed can only be assessed by lifetime follow up which no one has yet reported. Our own series with a follow up of 2-5 years was encouraging,¹ but more than half of the patients were still alive (despite being apparently at very high risk initially),¹ and many problems may have occurred subsequently.

The number of patients having stenting for bile duct stones in the King's series seems very high – no fewer than 40 of 146 of a consecutive series, including 27 (18%) as projected permanent treatment. The authors suggest that their low rate of duct clearance reflected their referral practice but referral centres should have special expertise. Of 343 patients with duct stones referred to this unit during the last two years, the clearance rate using standard techniques and mechanical lithotripsy was 94%. Stents were used as 'permanent' treat-




Figure: Triiodothyronine, thyroxine, free thyroxine, and thyroid stimulating hormone behaviour in a patient with chronic hepatitis C treated with 3 MU of IFN alfa 2-b for six months.

ment in only eight patients (2%). Three have already died within 6 months, of unrelated causes, and five remain well, so far.

We strive not to leave stents in on a permanent basis, believing that most patients can be managed effectively by expert endoscopy, radiology, and surgery, including adjunct techniques such as shock wave lithotripsy. Stenting is useful for a few weeks or months during which the patient's health and options can be reviewed. The King's group are rightly cautious in their recommendations. Stenting has not yet been shown to be a good permanent method for managing difficult stones, and should be used very sparingly.

P B COTTON
Duke University Medical Center,
Box 3341, Durham,
North Carolina 27710, USA

1 Cotton PB, Forbes A, Leung J, Dineen L. Endoscopic stenting for the long term treatment of large bile duct stones; 2 to 5 year follow up. *Gastrointest Endosc* 1987; 33: 411-2.

Reply

EDITOR,—In his letter, Dr Cotton raises two important points. The first is the high number of patients that were treated with an endoprosthesis and the second the adequacy of such a treatment in the long term. It is true that the number of patients treated with this approach in our series is high and this is because of two reasons. Firstly, it reflects the referral of some patients who had not responded to treatment in other experienced hands and secondly a conscious decision to achieve immediate drainage and clinical stabilisation in elderly and frail patients in whom we considered a protracted procedure might be more detrimental.

Dr Cotton places great emphasis upon duct clearance, but we would suggest that in some cases this may expose the patient to more risk than an in-dwelling prosthesis. There is a need for controlled data to answer these important points and we are pleased to confirm that we are now well into a multicentre study in a well defined 'high risk' group of patients.

D WESTABY
R PETERS
Gastrointestinal Unit,
Charing Cross Hospital,
Fulham Palace Road,
London W6 8RF

Assessment of proliferation of squamous, Barrett's, and gastric mucosa in patients with columnar lined Barrett's oesophagus

EDITOR,—I comment on the interesting paper by Iftikhar *et al* on assessment of proliferation in oesophageal squamous, Barrett's, and gastric epithelium by flow cytometric evaluation of Ki67 immunolabelling (*Gut* 1992; 33: 733-7). The authors found that biopsy specimens from squamous lined oesophagus contained cell populations with a higher percentage of Ki67 positive cells than Barrett's, and gastric mucosal biopsy specimens. Barrett's and gastric mucosal biopsy specimens having similar percentages of Ki67 positive cells.

Their results may be misleading as the proportion of stromal cells in Barrett's mucosa greatly exceeds that in gastric and squamous mucosal biopsy specimens, which have over 90% pure epithelial populations; stromal cells are not excluded from the total cell count by their technique and dilute the epithelial cell

population. Thus the finding that Barrett's mucosal biopsy specimens contain a similar percentage of Ki67 cells to gastric biopsy specimens (by this technique) is more likely to imply a considerably higher epithelial Ki67 labelling index in Barrett's than in gastric epithelial cell (as opposed to the total mucosal cell population).

This agrees with the studies performed on stained sections of mucosal biopsy specimens, including our own.¹ In our study of epithelial proliferation in Barrett's oesophagus we used PCNA immunostaining of specialised Barrett's, junctional, and gastric type metaplasia to evaluate proliferation in the epithelial cells only (excluding stromal cells). In our study specialised type Barrett's had a higher proportion of cells in cycle and an expansion of the proliferative compartment out of the crypt and into the luminal and gland cell compartments; implying a higher level of proliferative activity in the specialised Barrett's than in the other types of metaplasia. Our findings are consistent with the proved association of specialised type Barrett's epithelium with malignant change (in smokers).²⁻⁵

MICHAEL GRAY
Marine Villa,
LITTLE Lane,
Parkgate, Wirral L64 5SD

- 1 Gray MR, Hall PA, Lane DP, Nash J, Kingsnorth AN. Epithelial proliferation in Barrett's oesophagus - by PCNA immunolocalisation. *Gastroenterology* 1992; 103: 1769-76.
- 2 Gray MR, Kingsnorth AN. Barrett's oesophagus and ulcerative complications of reflux oesophagitis. *Gullet* 1993; 3 (suppl 1): 42-52.
- 3 Gray MR, Wallace HM, Golding H, Hoffman J, Kenyon WE, Kingsnorth AN. Polyamine metabolism in the columnar lined oesophagus. *Gut* (in press).
- 4 Gray MR, Donnelly R, Kingsnorth AN. The role of smoking and alcohol in metaplasia and cancer risk in Barrett's columnar lined oesophagus. *Gut* (in press).
- 5 Gray MR. Barrett's columnar lined oesophagus-pathogenesis and predisposition to malignancy. [Thesis] University of London, 1991.

Reply

EDITOR,—Thank you for giving us the opportunity to reply to Mr Gray's comments. We share his concern about the increased population of stromal cells in Barrett's oesophagus and it is for this reason that we selected the size of the gate for the epithelial cell populations identified by staining with anticytokeratin. This is clearly stated at the end of the second subsection in the methods section of our paper.

We have not had the opportunity to study the recent paper by Mr Gray and his colleagues² as it has not yet appeared in print. It would seem, however, that they have been examining different types of Barrett's metaplasia rather than comparing Barrett's mucosa with gastric or oesophageal squamous mucosa. The relevance of their results with respect to our findings is therefore difficult to understand.

S Y IFTIKHAR
R J C STEELE
S WATSON
P D JAMES
Department of Surgery,
University Hospital,
Nottingham NG7 2UH

Strategies for hepatitis B infection

EDITOR,—In their comprehensive leading article Catterall and Murray-Lyon (*Gut* 1992; 33: 576-9) discuss strategies for hepatitis B

immunisation. With regard to the need for booster vaccinations it seems to us that option I (no booster and reliance on immunological memory) has gained additional strength by new in vivo and in vitro data. Some of these have already been mentioned in the addendum. Our own data¹ have been supported by the findings of Jilg's group.^{2,3} To our knowledge, not a single case of clinically evident hepatitis B or carriage following hepatitis B virus infection has been reported in a confirmed serologically to hepatitis B vaccine.

A spot ELISA assay, which visualises the specific immunoglobulin production of either IgG or IgM class by individual mitogenically stimulated B cells in vitro, is able to show latent immunological memory and adds further support to this strategy.⁴ Long term follow up data confirm the presence of persisting circulating B cell memory despite undetectable anti-HBs in the serum seven to nine years after the first vaccination.⁵ Further studies with an even longer interval are in progress. Moreover, follow up data carefully monitoring the course of events after accidental infection (such as needlestick injuries) will give additional information.

Omitting booster vaccinations completely despite theoretical objections, in all those who have been known to react to the initial vaccination series with an anti-HBs titre in excess of 100 IU/l, seems to be a perfectly reasonable alternative to expensive, complicated, and probably unnecessary booster immunisation programmes. This policy is actually being evaluated on a world wide scale at present (be it uncontrolled) because many vaccinees with known responder status will not have received a booster vaccination.

P J WISMANS
Harbour Hospital,
Haringvliet 2,
3011 TD Rotterdam
The Netherlands
J VAN HATTUM
University Hospital Utrecht,
Heidelberglaan 100,
3508 GA Utrecht
The Netherlands

- 1 Wisman PJ, van Hattum J, Mudde GC, Endeman HJ, Poel J, de Gast GC. Is booster injection with hepatitis B vaccine necessary in healthy responders? A study of the immune response. *J Hepatol* 1989; 8: 236-40.
- 2 Jilg W, Schmidt M, Deinhardt F. Immune response to hepatitis B revaccination. *J Med Virol* 1988; 24: 377-84.
- 3 Jilg W, Schmidt M, Deinhardt F. Prolonged immunity after late booster dose of hepatitis B vaccine. *J Infect Dis* 1988; 157: 1267-9.
- 4 Wisman PJ, van Hattum J, de Gast GC, Endeman HJ, Poel J, Stolk B, *et al*. The spot-elisa assay: a sensitive in vitro method to study the immune response to hepatitis B surface antigen. *Clin Exp Immunol* 1989; 78: 75-8.
- 5 Van Hattum J, Maikoe T, Poel J, de Gast GC. In vitro anti-HBs production by individual B cells of responders to hepatitis B vaccine who subsequently lost antibody. In: Hollinger FB, Lemon SM, Margolis HS, eds. *Viral hepatitis and liver disease*. Baltimore: Williams & Wilkins, 1991: 774-6.

Overview of screening and management of familial adenomatous polyposis

EDITOR,—In their review article Rhodes and Bradburn (*Gut* 1992; 33: 125-31) emphasise the necessity, and potential benefits, of long term screening of family members and siblings of probands diagnosed as having familial adenomatous polyposis. These screening programmes have identified many affected subjects, usually by identification of rectal polyps at sigmoidoscopy,^{1,2} and reduced the occurrence of invasive colorectal carcinoma to less